Working party members and contributors

Cite this page

Cancer Council Australia Barrett's Oesophagus Guidelines Working Party. Guidelines:Barrett's/Working party members and contributors . In: Clinical practice guidelines for the diagnosis and management of Barrett’s Oesophagus and Early Oesophageal Adenocarcinoma. Sydney: Cancer Council Australia. [Version URL: https://wiki.cancer.org.au/australiawiki/index.php?oldid=86863, cited 2021 Jun 16]. Available from: https://wiki.cancer.org.au/australia/Guidelines:Barrett%27s.

Last modified:
15 September 2014 02:02:05

Working party members and contributors

Working party member	Clinical questions
Angelique Levert	Clinical question:Are there biomarkers for the diagnosis (presence) of BO? (body of evidence· view literature search summary)— Co-author Clinical question:Are there biomarkers that predict more accurately the risk of progression from BO to neoplasia? (body of evidence· view literature search summary)— Co-author Clinical question:Are there useful biomarkers to detect and improve the diagnosis of neoplasia in patients with or without BO? (body of evidence· view literature search summary)— Co-author
Associate Professor Alan Moss MBBS (Hons) MD, FRACP	Clinical question:What are the best modalities for accurately staging early oesophageal adenocarcinoma? (body of evidence· view literature search summary)— Author
Associate Professor Bernard Mark Smithers	Clinical question:How effective is endoscopic management compared with surgical management for high grade dysplasia in patients with BO? (body of evidence· view literature search summary)— Co-author
Associate Professor Christophe Rosty, MD PhD FRCPA	Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Co-author
Associate Professor Freddy Sitas	Clinical question:What is the incidence of neoplasia in patients with BO? (body of evidence· view literature search summary)— Author
Associate Professor Geoffrey Hebbard	Clinical question:What is appropriate medical systemic therapy for symptoms associated with BO? (body of evidence· view literature search summary)— Author
Associate Professor Guy Eslick	Clinical question:What is the prevalence of BO in the Australian population in comparison with other populations? (body of evidence· view literature search summary)— Author
Associate Professor Ian Norton MBBS, PhD, FRACP	Clinical question:What are the goals of treatment of high grade dysplasia in patients with BO? (body of evidence· view literature search summary)— Author
Associate Professor Jurgen Stahl FRCPA	Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Co-author
Associate Professor Neil Walker MD, FRCPA	Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Co-author
Associate Professor Sarah J (Sally) Lord MBBS MSc(Applied Biostatistics and Epidemiology)	Clinical question:Are there biomarkers for the diagnosis (presence) of BO? (body of evidence· view literature search summary)— Co-author Clinical question:Are there biomarkers that predict more accurately the risk of progression from BO to neoplasia? (body of evidence· view literature search summary)— Co-author Clinical question:Are there useful biomarkers to detect and improve the diagnosis of neoplasia in patients with or without BO? (body of evidence· view literature search summary)— Co-author
Clinical Professor Marian Priyanthi Kumarasinghe	Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Co-author
David Whiteman	Clinical question:Which factors best predict the risk of developing BO? (body of evidence· view literature search summary)— Author Clinical question:What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma? (body of evidence· view literature search summary)— Author Guidelines:Barrett's/Foreword — Author
Dr Adrian Chung MBBS, BMed Sci, FRACP	Clinical question:Are there any medical or surgical interventions that cause regression of BO? (body of evidence· view literature search summary)— Author
Dr Andrew Clouston MBBS PhD FRCPA	Clinical question:What are the histological features of early adenocarcinoma of the oesophagus? (body of evidence· view literature search summary)— Co-author Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Author
Dr Andrew Taylor MBBS MD FRACP	Clinical question:What is the appropriate management of low grade dysplasia in patients with BO? (body of evidence· view literature search summary)— Author
Dr Bradley Kendall MBBS, FRACP	Clinical question:How frequently should patients with BO undergo endoscopy? (body of evidence· view literature search summary)— Author
Dr Catherine Campbell MBBS, FRCPA	Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Co-author
Dr Darren A. Pavey MBBS FRACP	Clinical question:What is the best endoscopic treatment for high grade dysplasia in patients with BO? (body of evidence· view literature search summary)— Co-author
Dr Eric Y Lee BSc(Med) MBBS Hons FRACP	Clinical question:What is the optimal tissue sampling at endoscopy for diagnosis of BO? (body of evidence· view literature search summary)— Author
Dr Farzan Fahrtash Bahin, MBBS (Hons), MPhil (Med)	Clinical question:What is the best endoscopic management of early oesophageal adenocarcinoma? (body of evidence· view literature search summary)— Co-author
Dr Florian Grimpen, MD, FRACP	Clinical question:What endoscopic surveillance protocol should be followed for patients with BO and high grade dysplasia? (body of evidence· view literature search summary)— Co-author
Dr Henry To	Clinical question:Are there groups of patients with BO that can be discharged from surveillance? (body of evidence· view literature search summary)— Author Clinical question:Are there groups of patients with non-dysplastic BO that require more frequent surveillance? (body of evidence· view literature search summary)— Author
Dr Iain Thomson MBBS, FRACS	Clinical question:How effective is endoscopic management compared with surgical management for high grade dysplasia in patients with BO? (body of evidence· view literature search summary)— Author
Dr Ian Brown FRCPA	Clinical question:What are the histological features of early adenocarcinoma of the oesophagus? (body of evidence· view literature search summary)— Author Clinical question:What is the histological definition and grading of dysplasia in patients with BO? (body of evidence· view literature search summary)— Author Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Co-author
Dr Ian Faud Yusoff MBBS, FRACP	Clinical question:What is the endoscopic definition of BO and how is it described? (body of evidence· view literature search summary)— Author
Dr Jeremy Dwyer MBBS (Hons)	Clinical question:What are the best modalities for accurately staging early oesophageal adenocarcinoma? (body of evidence· view literature search summary)— Co-author
Dr Louisa Gordon	Clinical question:Is surveillance cost-effective for follow-up of patients with BO? (body of evidence· view literature search summary)— Author
Dr Luke Hourigan MBBS FRACP	Clinical question:After successful endoscopic treatment for BO neoplasia, how frequently should patients undergo endoscopy? (body of evidence· view literature search summary)— Author
Dr Mark Appleyard MD FRACP MRCP MBBS BSc	Clinical question:What endoscopic surveillance protocol should be followed for patients with BO and high grade dysplasia? (body of evidence· view literature search summary)— Author
Dr Mark Schoeman MBBS, PhD, FRACP, AGAF	Clinical question:Is there a role for ablative therapy to treat BO? (body of evidence· view literature search summary)— Author
Dr Oliver Maximilian Fisher, MD	Clinical question:Are there biomarkers for the diagnosis (presence) of BO? (body of evidence· view literature search summary)— Co-author Clinical question:Are there biomarkers that predict more accurately the risk of progression from BO to neoplasia? (body of evidence· view literature search summary)— Co-author Clinical question:Are there useful biomarkers to detect and improve the diagnosis of neoplasia in patients with or without BO? (body of evidence· view literature search summary)— Co-author
Dr Spiro Raftopoulos	Clinical question:What is the endoscopic definition of BO and how is it described? (body of evidence· view literature search summary)— Author
Dr Sutharshan Kannuthurai	Clinical question:What are the best modalities for accurately staging early oesophageal adenocarcinoma? (body of evidence· view literature search summary)— Co-author
Dr W Bastiaan de Boer MBBS, BMedSci, FRCPA	Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Co-author
Dr Yuri Veniaminovich Bobryshev PhD	Clinical question:What are the histological features of early adenocarcinoma of the oesophagus? (body of evidence· view literature search summary)— Author
Erfan Jaberiyanfar	Clinical question:What is the incidence of neoplasia in patients with BO? (body of evidence· view literature search summary)— Co-author
Melissa Thomas	Clinical question:Are there biomarkers for the diagnosis (presence) of BO? (body of evidence· view literature search summary)— Co-author Clinical question:Are there biomarkers that predict more accurately the risk of progression from BO to neoplasia? (body of evidence· view literature search summary)— Co-author Clinical question:Are there useful biomarkers to detect and improve the diagnosis of neoplasia in patients with or without BO? (body of evidence· view literature search summary)— Co-author
Ms Qingwei Luo	Clinical question:What is the incidence of neoplasia in patients with BO? (body of evidence· view literature search summary)— Co-author
Peter Sarich	Clinical question:What is the incidence of neoplasia in patients with BO? (body of evidence· view literature search summary)— Co-author
Professor David Watson MBBS, MD, FRACS	Clinical question:Are there any treatments that prevent progression of BO to cancer? (body of evidence· view literature search summary)— Author
Professor James Kench	Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Co-author
Professor Jon Emery MA, MBBCh, FRACGP, MRCGP, DPhil	Clinical question:For which populations is screening for BO cost-effective? (body of evidence· view literature search summary)— Author
Professor Michael Bourke MBBS, FRACP	Clinical question:What is the best endoscopic management of early oesophageal adenocarcinoma? (body of evidence· view literature search summary)— Author
Professor Prithi S Bhathal, MBBS PhD FRCPA	Clinical question:What is the histological definition of BO? (body of evidence· view literature search summary)— Co-author
Professor Rajvinder Singh MBBS MRCP MPhil FRACP AM FRCP	Clinical question:What are the best endoscopic techniques to detect and assess neoplasia within BO? (body of evidence· view literature search summary)— Author Clinical question:What are the endoscopic features of neoplasia (dysplasia and early cancer) within a BO segment? (body of evidence· view literature search summary)— Author
Professor Reginald V Lord MBBS MD FRACS	Clinical question:Are there biomarkers for the diagnosis (presence) of BO? (body of evidence· view literature search summary)— Author Clinical question:Are there biomarkers that predict more accurately the risk of progression from BO to neoplasia? (body of evidence· view literature search summary)— Author Clinical question:Are there useful biomarkers to detect and improve the diagnosis of neoplasia in patients with or without BO? (body of evidence· view literature search summary)— Author
Professor Shan Rajendra MBBCh, MSc, MRCP. MD, FRCP, FRCPE, FRACP	Clinical question:What is the best endoscopic treatment for high grade dysplasia in patients with BO? (body of evidence· view literature search summary)— Author
Sonali Munot	Clinical question:What is the incidence of neoplasia in patients with BO? (body of evidence· view literature search summary)— Co-author

Name	Affiliation
Prof Ian Olver AM	Working Party Convener, CEO, Cancer Council Australia
Derek Maule	Consumer representative to the Working Party
Cancer Council Australia Guideline Project and Technical Team
Christine Vuletich	Manager, Clinical guidelines Network, Cancer Council Australia until 3 July 2014
Jutta von Dincklage	Head, Clinical Guidelines Network 4 July 2014 - present Product Manager, Wiki Development, Cancer Council Australia 2010 - until 3 July 2014
Laura Wuellner	Project Manager, Clinical Guidelines Network Sept 2014- present
Laura Holliday	Project Officer, Systematic Literature Review, Clinical Guidelines Network, Cancer Council Australia 2012-2014
Emma Dickins	Project Officer, Systematic Literature Review, Clinical Guidelines Network, Cancer Council Australia 2014-present